ketamine and HbS Disease

ketamine has been researched along with HbS Disease in 26 studies

Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.

Research

Studies (26)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Incidence of Side Effects, Including Outlying Vital Signs

The patient will be assessed for vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation), Ramsay Sedation Scale (RSS) score at 5,10,20 minutes following medication administration and then every 20 minutes until a total of 120 minutes from the first dose of study medication. outlying vital signs recorded.( systolic Blood pressure less than 90mmHg or greater than 150mmHg, Heart rate less than 50bpm or greater than 150bpm, oxygen saturation below 90%, respiratory rate below 9breaths/minute or greater than 40breaths/minute and RSS of 1 or greater than 3) The RSS was used to asses the level of agitation or sedation caused by the intervention .the scale ranges from 1(anxious/agitated) to 6( no response to stimulus-deep sedation) with 2 being the optimal (cooperative, oriented and tranquil).A checklist for side effects like airway problems, allergic reactions, salivation, dysphoria,nystagmus, respiratory/cardiac arrest, awakening hallucinations, nausea/vomiting was used (NCT02434939)
Timeframe: 5, 10, 20, 40, 60, 80, 100, 120 minutes post drug administration

Incidence of Treatment Failure by Treatment Group.

Requiring more than two doses of the study medication provided for adequate pain control (NCT02434939)
Timeframe: 120 minutes

Maximal Change in NRS Pain Scores as a Percentage of Baseline NRS Pain Score.

Our primary outcome measurement was the maximum change on the verbal NRS pain scale compared with their initial score (baseline). The NRS was used to measure a patient's subjective level of pain on a scale from 0 (representing no pain at all) to 10 (the worst pain imaginable) using whole numbers. The NRS score was documented just prior to the administration of the study drug (time zero). After infusion of the study drug was complete, NRS scores were documented at 5, 10, 20, and then every 20 minutes thereafter up to 120 minutes. We stopped recording NRS scores prior to 120 minutes if the patient requested a third dose of the study drug, withdrew consent or developed a severe adverse effect. (NCT02434939)
Timeframe: 5, 10, 20,25,30, 40,45,50 60, 80, 100, 120 minutes post drug adminstration

Time to Maximal Analgesic Effect and Duration of Action of Ketamine

"Following dosage with study medication, the amount of time taken to demonstrate the maximal change in the patient's NRS pain score.~Maximal change in NRS pain score is to be defined as the largest change from patient's baseline pain score. Duration of maximal change is how long the patient's pain score remained at this level." (NCT02434939)
Timeframe: 5, 10, 20, 40, 60, 80, 100, 120 minutes post drug administration

Effect of Low-dose Ketamine (LDK) on Opioid Usage in the ED

Opioid usage for at least one but up to three prior patient visits in the last one year for each patient enrolled in the study was summarized, expressed as morphine equivalents in mg/kg/h, to account for different types of opioids used per patient preference, and then this was compared to the intervention group that received LDK. Percent change in opioid usage (expressed as morphine equivalents in mg/kg/h) is reported). (NCT03296345)
Timeframe: Up to one year prior and after LDK administration on day 1 of the study in the ED

Effect of Low-dose Ketamine on Discharge Rates From the ED

"Percent discharge from the ED for intervention group and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. Participants were assigned a 0 if discharged or 1 if not discharged." (NCT03296345)
Timeframe: Up to one year prior to receipt of ketamine for the historical control arm/group and up to 18 months for the intervention arm/group

Effect of Low-dose Ketamine on Pain Scores on Presentation to the ED

Patient pain scores at presentation for the enrolled encounters and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior and on presentation to the ED after LDK administration

Effect of Low-dose Ketamine on Patient Pain Scores on Discharge From the ED/Admission to the Hospital

Patient pain scores at time of discharge from the ED/admission to the hospital for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain scores post receipt of ketamine are presented for the intervention group. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: At time of discharge from the ED/admission to the hospital (up to one year prior and after LDK administration)

Effect of Low-dose Ketamine on Percent Difference of Length of Stay (LOS) in the ED

Length of stay (LOS) in minutes in the ED for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED

Effect of Low-dose Ketamine on Time to 50% Pain Reduction

Time to 50% pain reduction (pain reported 50% less than baseline) in minutes for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed as historical controls. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED

Subjective Effect of Low Dose Ketamine on Pain Relief Assessed Via a Patient Survey

"After receipt of LDK, patients and/or their parents, based on age, filled out a survey based on a Likert scale regarding their agreement (Strongly Disagree to Strongly Agree) with the following statements: Achieved faster pain relief with LDK, Achieved more complete pain relief with LDK, and Desire to receive LDK in a future vaso-occlusive crisis. There is also an area where patients could provide general comments regarding their experience in receiving LDK.~Count of Participants who agree or strongly agree for each question are reported." (NCT03296345)
Timeframe: after LDK administration on day 1 of the study in the ED

Number of Participants With an Adverse Effects

We will monitor for adverse effects and record for changes in vital signs including nausea and vomiting, hypotension, respiratory depression, laryngospasm, and emotional and psychological effects (emergence reactions). (NCT02430818)
Timeframe: 60 minutes

Pain Treatment-VAS (Visual Analog Scale)

Study outcomes involve change in participants' pain as measured by a visual analog scale. The scale is a 10 inch line from 0 to 10 inches with 10 being the most pain and 0 being no pain. There are no units on the scale; it is just a straight line from no pain (0) to the worst pain (10). We assessed at o, 15, and 60 minutes but only scored the VAS at 60 minutes. (NCT02430818)
Timeframe: At 0 minutes and 60 minutes

Would the Participant Would Consider Using the Drug Given to Them for Pain Relief in the Future

Patients will be assessed to determine whether the participant would consider using the drug given to them for pain relief in the future. It was measured on a likert scale from 1-5 with 1 being did not like and would not use the drug again to 5 being like and would definitely receive the medication again. There are no units. The numbers below are the total number of patients that completed this answer. This was only asked on patients that received medication as if they did not receive medication the answer would not make sense. The median value is the likert value on a scale of 1-5 with the standard deviation. (NCT02430818)
Timeframe: 60 minutes

Reviews

5 reviews available for ketamine and HbS Disease

Trials

4 trials available for ketamine and HbS Disease

Other Studies

17 other studies available for ketamine and HbS Disease